A possible new treatment for a common type of heart failure has been identified by researchers at the University of Colorado (CU) School of Medicine.
Researchers examined the effect of an investigational drug called givinostat on diastolic dysfunction. This condition is a heart relaxation abnormality that contributes to heart failure with preserved ejection fraction (HFpEF). The results were published in the journal Science Translational Medicine on 7 February.
There is currently no effective treatment for HFpEF. The condition affects millions of people worldwide and is characterised by left ventricular diastolic dysfunction and can be a result of hypertension, diabetes, ageing or other conditions. In cases of HFpEF, the heart pumps blood normally but is unable to fill as efficiently as a healthy heart.